Cost utility analysis of the SQ(®) HDM SLIT-tablet in house dust mite allergic asthma patients in a German setting

BACKGROUND: Asthma affects an estimated 300 million people worldwide with the condition associated with significant healthcare utilisation costs and a large impact on patient quality of life. The SQ(®) HDM SLIT-tablet (ACARIZAX(®), Hørsholm, Denmark) is a sublingually administered allergy immunother...

Descripción completa

Detalles Bibliográficos
Autores principales: Hahn-Pedersen, J., Worm, M., Green, W., Andreasen, J. Nørgaard, Taylor, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015209/
https://www.ncbi.nlm.nih.gov/pubmed/27610217
http://dx.doi.org/10.1186/s13601-016-0127-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015209/
https://www.ncbi.nlm.nih.gov/pubmed/27610217
http://dx.doi.org/10.1186/s13601-016-0127-6

Ejemplares similares